| DIRECT COMPETITOR COMPARISON | |
| CRTX | AZN | GSK | MRK | Industry | | Market Cap: | 134.61M | 67.25B | 107.21B | 78.02B | 104.49M | | Employees: | 107 | 65,000 | 99,003 | 55,200 | 63 | | Qtrly Rev Growth (yoy): | 12.10% | 5.50% | 14.90% | 1.80% | 19.10% | | Revenue (ttm): | 99.54M | 32.05B | 43.37B | 23.37B | 13.84M | | Gross Margin (ttm): | 65.67% | 82.24% | 76.27% | 76.36% | 65.67% | | EBITDA (ttm): | 18.73M | 13.52B | 17.09B | 7.81B | -11.86M | | Oper Margins (ttm): | 15.69% | 37.85% | 34.30% | 26.63% | -149.46% | | Net Income (ttm): | 10.38M | 7.22B | 7.79B | 8.05B | N/A | | EPS (ttm): | 0.697 | 4.98 | 3.05 | 3.808 | -0.31 | | P/E (ttm): | 7.69 | 9.31 | 13.87 | 9.71 | 17.48 | | PEG (5 yr expected): | N/A | N/A | 3.01 | 2.65 | 1.35 | | P/S (ttm): | 1.34 | 2.08 | 2.46 | 3.36 | 10.13 |
|
| AZN = AstraZeneca plc | | GSK = GlaxoSmithKline plc | | MRK = Merck & Co. Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|